CO22 Health-Related Quality of Life from a Phase 4 Global Clinical Study to Evaluate Discontinuation and Rechallenge of Pexidartinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) Previously Treated with Pexidartinib
Jun 1, 2024, 00:00 AM
10.1016/j.jval.2024.03.111
https://www.valueinhealthjournal.com/article/S1098-3015(24)00226-2/fulltext
Section Title :
Section Order :
10516
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00226-2&doi=10.1016/j.jval.2024.03.111